Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23912273 | 0.97 | MAPK1 (0.46) | MAPK1 | |
| SCHEMBL17808362 | 0.93 | MAPK1 (0.41) | MAPK1 | |
| SCHEMBL22043708 | 0.93 | MAPK1 (0.41) | MAPK1 | |
| SCHEMBL15281172 | 0.86 | MAPK1 (0.35) | MAPK1 | |
| SCHEMBL7224887 | 0.81 | — | — | |
| SCHEMBL15907943 | 0.81 | MAPK1 (0.56) | MAPK1ALDH1A1HSD17B10 | |
| SCHEMBL7232312 | 0.81 | MAPK1 (0.56) | MAPK1ALDH1A1HSD17B10 | |
| SCHEMBL18643579 | 0.81 | — | — | |
| SCHEMBL862038 | 0.81 | — | — | |
| SCHEMBL3075445 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 340 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113861128-A | Polymerizable compound and optically anisotropic body | 江苏创拓新材料有限公司 | 2021-12-31 | — | — | CN | claimed |
| EP-3729442-A1 | MOLECULE-BASED EQUATION ORIENTED REACTOR SIMULATION SYSTEM AND ITS MODEL REDUCTION | Aspen Technology, Inc. (US) | 2020-10-28 | — | — | EP | claimed |
| US-20190228843-A1 | Molecule-Based Equation Oriented Reactor Simulation System And Its Model Reduction | JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT | 2019-07-25 | — | — | US | claimed |
| EP-1852420-B1 | Indole compounds for treating respiratory disorders | ONO PHARMACEUTICAL CO (JP) | 2012-10-17 | — | — | EP | claimed |
| US-20250349883-A1 | MODIFIED SULFIDE SOLID ELECTROLYTE AND PRODUCTION METHOD THEREFOR, AND ELECTRODE COMPOSITE MATERIAL AND LITHIUM ION BATTERY | IDEMITSU KOSAN CO.,LTD. (JP) | 2025-11-13 | — | — | US | disclosed |
| US-20250316750-A1 | MODIFIED SULFIDE SOLID ELECTROLYTE, PRODUCTION METHOD FOR SAME, ELECTRODE MIXTURE, AND LITHIUM-ION BATTERY | IDEMITSU KOSAN CO.,LTD. (JP) | 2025-10-09 | — | — | US | disclosed |
| CN-119547157-A | Modified sulfide solid electrolyte, manufacturing method thereof, electrode composite material and lithium ion battery | 出光兴产株式会社 | 2025-02-28 | — | — | CN | disclosed |
| CN-119404261-A | Modified sulfide solid electrolyte, manufacturing method thereof, electrode composite material and lithium ion battery | 出光兴产株式会社 | 2025-02-07 | — | — | CN | disclosed |
| CN-114605350-B | Polymerizable compound, polymerizable composition containing same, and optically anisotropic body | 江苏创拓新材料有限公司 | 2024-09-13 | — | — | CN | disclosed |
| WO-2024024824-A1 | MODIFIED SULFIDE SOLID ELECTROLYTE, PRODUCTION METHOD FOR SAME, ELECTRODE MIXTURE, AND LITHIUM-ION BATTERY | 出光興産株式会社 | 2024-02-01 | — | — | WO | disclosed |
| WO-2024024825-A1 | MODIFIED SULFIDE SOLID ELECTROLYTE AND PRODUCTION METHOD THEREFOR, AND ELECTRODE COMPOSITE MATERIAL AND LITHIUM ION BATTERY | 出光興産株式会社 | 2024-02-01 | — | — | WO | disclosed |
| WO-2024013275-A1 | MATERIALS FOR ELECTRONIC DEVICES | MERCK PATENT GMBH (DE) | 2024-01-18 | — | — | WO | disclosed |
| US-20040077643-A1 | 3,4 Dihydroisoquinoline derivative compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-04-22 | — | — | US | disclosed |
| EP-1405848-A1 | TETRAHYDROQUINOLINE DERIVATIVE COMPOUND AND DRUG CONTAINING THE COMPOUND AS ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-04-07 | — | — | EP | disclosed |
| US-20040063936-A1 | Pyrimidine derivatives and process for preparing the same | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-04-01 | — | — | US | disclosed |
| EP-1378509-A1 | DRUGS CONTAINING TRIAZASPIRO 5.5]UNDECANE DERIVATIVES AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-01-07 | — | — | EP | disclosed |
| EP-1346985-A1 | PYRIMIDINE DERIVATIVES AND PROCESS FOR PREPARING THE SAME | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-09-24 | — | — | EP | disclosed |
| EP-1306373-A1 | 3,4-DIHYDROISOQUINOLINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-05-02 | — | — | EP | disclosed |
| EP-1236726-A1 | TRIAZASPIRO 5.5]UNDECANE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-09-04 | — | — | EP | disclosed |
| EP-1215203-A1 | HYDROXAMIC ACID DERIVATIVES, PROCESS FOR THE PRODUCTION THEREOF AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-06-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063936-A1 | Pyrimidine derivatives and process for preparing the same | DPYD, NUDT1, UMPS | MAPK1 400/4885ALDH1A1 134/4885HSD17B10 2590/4885 |
| US-20040077643-A1 | 3,4 Dihydroisoquinoline derivative compounds and drugs containing these compounds as the active ingredient | CNR1, CNR2, TRPV1 | MAPK1 196/4885ALDH1A1 2167/4885HSD17B10 3830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.